Sugi Predict

Sugi Predict / Compounds / SCHEMBL14945382

SCHEMBL14945382

SCHEMBL14945382

CCOc1ccccc1[C@H](CO)OC1CCOCC1

nearest known ligand 0.47

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ ACACA Q13085 10/20 0.47
▸ NPSR1 Q6W5P4 1/20 0.40
▸ ACACB O00763 6/20 0.40
▸ KAT2B Q92831 1/20 0.39
▸ BAZ2B Q9UIF8 1/20 0.39
▸ ADRB2 P07550 1/20 0.38
▸ ADRB1 P08588 1/20 0.38
▸ ADRB3 P13945 1/20 0.38
▸ ABCB1 P08183 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21876832 1.00 ACACA (0.47) ACACANPSR1ACACBKAT2BBAZ2B
SCHEMBL29642175 0.89 ACACB (0.47) ACACAACACB
SCHEMBL21816549 0.89 ACACB (0.47) ACACAACACB
SCHEMBL29700513 0.89 ACACB (0.47) ACACAACACB
SCHEMBL14945398 0.89 ACACB (0.47) ACACAACACB
SCHEMBL14945397 0.89 ACACB (0.47) ACACAACACB
SCHEMBL21816453 0.87 ACACA (0.48) ACACAACACB
SCHEMBL14945460 0.86 ABCB1 (0.40) ACACAACACBABCB1
SCHEMBL14945585 0.86 ACACB (0.41) ACACAACACBKAT2BBAZ2B
SCHEMBL21816530 0.85 ACACA (0.49) ACACAACACB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912718-B2 Solid forms of a thienopyrimidinedione ACC inhibitor and methods for production thereof GILEAD APOLLO, LLC (US) 2024-02-27 — — US disclosed
US-11912718-B2 Solid forms of a thienopyrimidinedione ACC inhibitor and methods for production thereof GILEAD APOLLO, LLC (US) 2024-02-27 — — US disclosed
US-20200102323-A1 ACC INHIBITORS AND USES THEREOF SCHRÖDINGER, INC. 2020-04-02 — — US disclosed
EP-3329919-B1 ACC INHIBITORS AND USES THEREOF GILEAD APOLLO LLC (US) 2019-11-06 — — EP disclosed
US-20190225623-A1 SOLID FORMS OF A THIENOPYRIMIDINEDIONE ACC INHIBITOR AND METHODS FOR PRODUCTION THEREOF NIMBUS DISCOVERY, INC. 2019-07-25 — — US disclosed
US-10183951-B2 Solid forms of a thienopyrimidinedione ACC inhibitor and methods for production thereof GILEAD APOLLO, LLC (US) 2019-01-22 — — US disclosed
EP-3329919-A1 ACC INHIBITORS AND USES THEREOF Gilead Apollo, LLC (US) 2018-06-06 — — EP disclosed
US-9944655-B2 ACC inhibitors and uses thereof GILEAD APOLLO, LLC (US) 2018-04-17 — — US disclosed
US-9944655-B2 ACC inhibitors and uses thereof GILEAD APOLLO, LLC (US) 2018-04-17 — — US disclosed
US-20170267690-A1 SOLID FORMS OF A THIENOPYRIMIDINEDIONE ACC INHIBITOR AND METHODS FOR PRODUCTION THEREOF J.P. LAWSON CONSULTING LLC 2017-09-21 — — US disclosed
US-20170267690-A1 SOLID FORMS OF A THIENOPYRIMIDINEDIONE ACC INHIBITOR AND METHODS FOR PRODUCTION THEREOF J.P. LAWSON CONSULTING LLC 2017-09-21 — — US disclosed
US-20160297834-A1 ACC INHIBITORS AND USES THEREOF GILEAD APOLLO, LLC 2016-10-13 — — US disclosed
US-20160297834-A1 ACC INHIBITORS AND USES THEREOF GILEAD APOLLO, LLC 2016-10-13 — — US disclosed
US-20150203510-A1 ACC INHIBITORS AND USES THEREOF GILEAD APOLLO, LLC 2015-07-23 — — US disclosed
US-20150203510-A1 ACC INHIBITORS AND USES THEREOF GILEAD APOLLO, LLC 2015-07-23 — — US disclosed
US-8969557-B2 ACC inhibitors and uses thereof Nimbus Apollo, Inc. (US) 2015-03-03 — — US disclosed
US-8969557-B2 ACC inhibitors and uses thereof Nimbus Apollo, Inc. (US) 2015-03-03 — — US disclosed
US-20130123231-A1 ACC INHIBITORS AND USES THEREOF Nimbus Apollo, Inc. (US) 2013-05-16 — — US disclosed
US-20130123231-A1 ACC INHIBITORS AND USES THEREOF Nimbus Apollo, Inc. (US) 2013-05-16 — — US disclosed
WO-2013071169-A1 ACC INHIBITORS AND USES THEREOF Nimbus Apollo, Inc. (US) 2013-05-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200102323-A1 ACC INHIBITORS AND USES THEREOF ACACA, ACACB, ACAT2 ACACA 1/4885NPSR1 4515/4885ACACB 2/4885
US-20170267690-A1 SOLID FORMS OF A THIENOPYRIMIDINEDIONE ACC INHIBITOR AND METHODS FOR PRODUCTION THEREOF ACACA, ACACB, COASY ACACA 1/4885NPSR1 4832/4885ACACB 2/4885
US-11912718-B2 Solid forms of a thienopyrimidinedione ACC inhibitor and methods for production thereof ACACA, ACACB, COASY ACACA 1/4885NPSR1 4832/4885ACACB 2/4885
US-20150203510-A1 ACC INHIBITORS AND USES THEREOF ACACA, ACACB, ACAT2 ACACA 1/4885NPSR1 4515/4885ACACB 2/4885
US-10183951-B2 Solid forms of a thienopyrimidinedione ACC inhibitor and methods for production thereof ACACA, ACACB, COASY ACACA 1/4885NPSR1 4832/4885ACACB 2/4885
US-20190225623-A1 SOLID FORMS OF A THIENOPYRIMIDINEDIONE ACC INHIBITOR AND METHODS FOR PRODUCTION THEREOF ACACA, ACACB, COASY ACACA 1/4885NPSR1 4832/4885ACACB 2/4885
US-20130123231-A1 ACC INHIBITORS AND USES THEREOF ACACA, ACACB, ACAT2 ACACA 1/4885NPSR1 4515/4885ACACB 2/4885
US-20160297834-A1 ACC INHIBITORS AND USES THEREOF ACACA, ACACB, ACAT2 ACACA 1/4885NPSR1 4515/4885ACACB 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.